External phenome analysis enables a rational federated query strategy to detect changing rates of treatment-related complications associated with multiple myeloma
Jeremy L. Warner(Brown University), Robin Joyce(Beth Israel Deaconess Medical Center), Kelly Bodio(Beth Israel Deaconess Medical Center), Gil Alterovitz(Brigham and Women's Hospital)
Cited by 13
Related Papers
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma
|Blood|2010|866
A CRISPR-Cas12a-derived biosensing platform for the highly sensitive detection of diverse small molecules
|Nature Communications|2019|424
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
|Journal of Immunotherapy|2011|285